药物对比
Bexagliflozin vs Vildagliptin
Bexagliflozin 与 Vildagliptin：SGLT2抑制剂与DPP-4抑制剂治疗2型糖尿病。比较疗效、心血管获益、副作用及哪种口服药物可能更适合您。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when choosing between an SGLT2 inhibitor and a DPP-4 inhibitor for type 2 diabetes patients with or without cardiovascular or renal disease.
结论
Neither is universally superior; Bexagliflozin offers extra organ protection while Vildagliptin provides reliable, well-tolerated glycemic control.
全部药物对比